Brokers Offer Predictions for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Research analysts at Wedbush issued their Q1 2026 EPS estimates for shares of Day One Biopharmaceuticals in a report released on Wednesday, May 7th. Wedbush analyst R. Driscoll expects that the company will post earnings per share of ($0.31) for the quarter. Wedbush currently has a "Outperform" rating and a $25.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.33) EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.11. The business had revenue of $30.76 million during the quarter, compared to analyst estimates of $30.28 million.

Several other analysts also recently weighed in on DAWN. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Needham & Company LLC decreased their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Wednesday. The Goldman Sachs Group lowered their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a report on Tuesday, March 25th. Finally, JPMorgan Chase & Co. reduced their price objective on Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of "Buy" and an average price target of $30.57.

Day One Biopharmaceuticals Trading Down 9.9 %

Day One Biopharmaceuticals stock opened at $6.30 on Thursday. The stock has a 50 day moving average of $7.77 and a two-hundred day moving average of $11.21. Day One Biopharmaceuticals has a twelve month low of $6.26 and a twelve month high of $17.14. The stock has a market capitalization of $638.53 million, a price-to-earnings ratio of -6.12 and a beta of -1.24.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in Day One Biopharmaceuticals by 73.9% in the 4th quarter. FMR LLC now owns 12,887,467 shares of the company's stock valued at $163,284,000 after buying an additional 5,475,087 shares during the period. Franklin Resources Inc. boosted its position in shares of Day One Biopharmaceuticals by 0.3% in the fourth quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company's stock worth $49,197,000 after acquiring an additional 13,320 shares during the last quarter. Estuary Capital Management LP grew its holdings in Day One Biopharmaceuticals by 35.5% in the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock valued at $47,092,000 after purchasing an additional 972,997 shares during the period. Pictet Asset Management Holding SA increased its position in Day One Biopharmaceuticals by 17.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company's stock worth $44,219,000 after purchasing an additional 507,398 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth $31,829,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares of the company's stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock valued at $251,925. 6.20% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.